Latest Biotech News

A multicenter Phase Ib/II trial reported clinically meaningful responses combining fruquintinib, a VEGFR inhibitor, with sintilimab, an anti‑PD‑1 antibody, in patients with...

A Nature Communications target trial emulation found that nirmatrelvir/ritonavir (Paxlovid) and molnupiravir reduced the risk of cardiovascular events after COVID‑19 infection. The study used...

The FDA approved Cytokinetics’ Myqorzo to treat obstructive hypertrophic cardiomyopathy, marking the company’s first U.S. drug approval after a multi-decade effort. The clearance positions...

BioMarin agreed to acquire Amicus Therapeutics for $4.8 billion, adding two approved enzyme-replacement therapies for Fabry and Pompe diseases and strengthening BioMarin’s rare-disease commercial...

Regulators and sponsors paused parts of a phase III antibody‑drug conjugate (ADC) program after an unexpected cluster of fatal interstitial lung disease (ILD) events. The FDA placed a partial hold...

The White House announced a set of agreements with nine major drugmakers designed to lower U.S. drug prices by aligning some Medicare/Medicaid prices with peer‑nation levels. Companies named in...

South Korean AI‑driven protein discovery firm Galux signed a research agreement with Boehringer Ingelheim to explore AI‑guided, purpose‑specific protein molecule design. Galux will validate...

Two commercial collaborations aim to expand high‑throughput functional genomics and epigenomics. Parse Biosciences struck a deal with Codebreaker Labs to combine engineered variant libraries with...

Swedish spinout Epigenovo is commercializing scFFPE‑ATAC, a high‑throughput single‑cell chromatin‑accessibility assay compatible with formalin‑fixed paraffin‑embedded (FFPE) tissues. The method,...

AbCellera and Bruker reached a settlement resolving longstanding patent litigation tied to single‑cell antibody discovery and microfluidic technologies. Under the agreement Bruker will pay...

The Jackson Laboratory completed its acquisition of the New York Stem Cell Foundation and held a ribbon‑tying event to mark the launch of a unified nonprofit research organization in New York...

BioCentury reported a clinical setback for Insmed’s Brinsupri that triggered a sharp market reaction and a reduction in the company’s market capitalization. The report details clinical data or...

BioMarin agreed to acquire Amicus Therapeutics for $4.8 billion in cash, consolidating two rare-disease portfolios. The deal transfers Amicus’ approved therapies for Fabry (Galafold) and Pompe...

The FDA granted Cytokinetics its first U.S. drug approval for Myqorzo to treat obstructive hypertrophic cardiomyopathy, ending a 27-year pursuit for the company. Cytokinetics said it will begin...

Daiichi Sankyo paused enrollment in the phase III IDeate-Lung02 study of the antibody-drug conjugate ifinatamab deruxtecan following a higher-than-anticipated incidence of fatal interstitial lung...

Swedish spinout Epigenovo is commercializing scFFPE-ATAC, a high‑throughput single-cell chromatin accessibility assay compatible with formalin‑fixed paraffin‑embedded (FFPE) tissue. The company...

South Korean AI-protein design firm Galux signed a research agreement with Boehringer Ingelheim to explore AI-driven design of purpose-specific protein therapeutics. Galux will validate AI methods...

Parse Biosciences and Codebreaker Labs launched a collaboration to couple Codebreaker’s engineered variant libraries with Parse’s single-cell transcriptomics to determine how genetic variants...

Wasatch BioLabs and Agilent announced a co-marketing agreement for a targeted nanopore methylation sequencing assay developed jointly and available under early access. The service pairs Wasatch’s...

A Nature Communications study reported that targeted antisense oligonucleotide (ASO) therapy reversed developmental defects in spinal muscular atrophy (SMA) organoid models. The team demonstrated...